These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines. Dufies M; Cassuto O; Jacquel A; Robert G; Auberger P Cell Cycle; 2013 Jun; 12(11):1645-6. PubMed ID: 23673326 [No Abstract] [Full Text] [Related]
44. Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors. Kuo YH; Wei SH; Jiang JH; Chang YS; Liu MY; Fu SL; Huang CF; Lin WJ Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830455 [TBL] [Abstract][Full Text] [Related]
45. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603 [TBL] [Abstract][Full Text] [Related]
47. Suppression of autophagy by BCR/ABL. Calabretta B; Salomoni P Front Biosci (Schol Ed); 2012 Jan; 4(2):453-60. PubMed ID: 22202070 [TBL] [Abstract][Full Text] [Related]
48. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F; Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665 [TBL] [Abstract][Full Text] [Related]
49. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review. Singh P; Kumar V; Gupta SK; Kumari G; Verma M Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624 [TBL] [Abstract][Full Text] [Related]
50. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425 [TBL] [Abstract][Full Text] [Related]
51. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1 Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462 [TBL] [Abstract][Full Text] [Related]